Bicycle Therapeutics

Update in progress

BCYC (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Bicycle Therapeutics plc is a clinical-stage UK biopharma developing bicycle toxin conjugates and related therapies for underserved diseases in the US and UK. Its pipeline includes zelenectide pevedotin (phase II, nectin-4), nuzefatide pevedotin (phase I/II, EphA2), BT7480 (phase I/II, nectin-4/CD137), and BT1702 (MT1-MMP theranostic; IND-enabling). It pursues preclinical CNS, neuromuscular, and radiopharmaceutical programs and collaborates with Bayer, Novartis, Ionis, Genentech, and AstraZeneca. Based in Cambridge since 2009.

Company score

Sentiment: 0.00; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.00; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.00; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqGS (NMS)
LocationUnited Kingdom
CEODr. Kevin Lee M.B.A., Ph.D.
Founded2009
Employees288
Websitewww.bicycletherapeutics.com

Identifiers

ISINUS0887861088
FIGIBBG00P0YWPK6
CUSIP088786108
CIK0001761612